Sulfonamide derivatives
AssigneeEli Lilly and Company
InventorsJames Allen Knobelsdorf, Timothy Alan Shepherd, Eric George Tromiczak, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
Life of this patent
Estimating the term…
Abstract
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders 1
Claims23
A compound of the formula:
- 107
- wherein A represents
- 108 109
- R represents hydrogen or (1-4C)alkyl;
- R1 represents (1-6C)alkyl, (2-6C)alkenyl, or NR9R10;
- R2 and R3 each independently represent hydrogen, (1-4C)alkyl, F, or —OR11;
- R4a and R4b each independently represent hydrogen, (1-4C) alkyl, (1-4C)alkoxy, I, Br, Cl, or F;
- R5 and R6 each independently represent hydrogen, (1-4C)alkyl, F, or —OR11;
- R7 represents hydrogen, or (1-4C)alkyl;
- R8 represents (1-6C)alkyl, unsubstituted or substituted aromatic group, unsubstituted or substituted heteroaromatic group, cycloalkyl, or alkylcycloalkyl;
- n is zero or an integer 1, 2, 3, 4, or 5;
- m is zero or an integer 1, 2, 3, 4, or 5;
- p is an integer 1 or 2;
- R9 and R10 each independently represent hydrogen or (1-4C)alkyl;
- and
- R11 represents hydrogen or (1-4C)alkyl;
- or a pharmaceutically acceptable salt thereof.
A method of potentiating glutamate receptor function in a patient, which comprises administering to said patient an effective amount of a compound of formula:
- 112
- wherein A represents
- 113 114
- R represents hydrogen or (1-4C)alkyl;
- R1 represents (1-6C)alkyl, (2-6C)alkenyl, or NR9R10;
- R2 and R3 each independently represent hydrogen, (1-4C)alkyl, F, or —OR11;
- R4a and R4b each independently represent hydrogen, (1-4C) alkyl, (1-4C)alkoxy, I, Br, Cl, or F;
- R5 and R6 each independently represent hydrogen, (1-4C)alkyl, F, or —OR11;
- R7 represents hydrogen, or (1-4C)alkyl;
- R8 represents (1-6C)alkyl, unsubstituted or substituted aromatic group, unsubstituted or substituted heteroaromatic group, cycloalkyl, or alkylcycloalkyl;
- n is zero or an integer 1, 2, 3, 4, or 5;
- m is zero or an integer 1, 2, 3, 4, or 5;
- p is an integer 1 or 2;
- R9 and R10 each independently represent hydrogen or (1-4C)alkyl;
- and
- R11 represents hydrogen or (1-4C)alkyl;
- or a pharmaceutically acceptable salt thereof.
A method of treating Alzheimers disease in a patient, which comprises administering to said patient in need thereof an effective amount of a compound of formula:
- 115
- wherein A represents
- 116 117
- R represents hydrogen or (1-4C)alkyl;
- R1 represents (1-6C)alkyl, (2-6C)alkenyl, or NR9R10;
- R2 and R3 each independently represent hydrogen, (1-4C)alkyl, F, or —OR11;
- R4a and R4b each independently represent hydrogen, (1-4C) alkyl, (1-4C)alkoxy, I, Br, Cl, or F;
- R5 and R6 each independently represent hydrogen, (1-4C)alkyl, F, or —OR11;
- R7represents hydrogen, or (1-4C)alkyl;
- R8 represents (1-6C)alkyl, unsubstituted or substituted aromatic group, unsubstituted or substituted heteroaromatic group, cycloalkyl, or alkylcycloalkyl;
- n is zero or an integer 1, 2, 3, 4, or 5;
- m is zero or an integer 1, 2, 3, 4, or 5;
- p is an integer 1 or 2;
- R9 and R10 each independently represent hydrogen or (1-4C)alkyl;
- and
- R11 represents hydrogen or (1-4)alkyl;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.